Literature DB >> 3326741

Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis.

T Jensen1, S S Pedersen, N Høiby, C Koch.   

Abstract

The clinical efficacy of the conventional aminoglycoside plus beta-lactam treatment was compared to that of monotherapy with oral quinolones in 26 adult cystic fibrosis patients in an open prospective clinical trial in which six two-week courses of antipseudomonas treatment were administered with an interval of approximately three months between treatments. In each patient two courses of conventional treatment were followed by two courses of quinolone treatment and then by another two courses of conventional treatment. The observed improvements in pulmonary function were somewhat higher when the patients received conventional treatments, and in the most seriously affected patients conventional treatment was significantly better than quinolone treatment. On the basis of these findings it is suggested that quinolone monotherapy cannot replace conventional antipseudomonal chemotherapy in patients with severe pulmonary involvement.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3326741     DOI: 10.1007/bf02013055

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  17 in total

1.  Resistance to ciprofloxacin.

Authors:  S T Chapman; D C Speller; D S Reeves
Journal:  Lancet       Date:  1985-07-06       Impact factor: 79.321

2.  Ciprofloxacin-resistant Pseudomonas.

Authors:  C M Roberts; J Batten; M E Hodson
Journal:  Lancet       Date:  1985-06-22       Impact factor: 79.321

3.  Does centralized treatment of cystic fibrosis increase the risk of Pseudomonas aeruginosa infection?

Authors:  S S Pedersen; T Jensen; T Pressler; N Høiby; K Rosendal
Journal:  Acta Paediatr Scand       Date:  1986-09

4.  Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection.

Authors:  M Szaff; N Høiby; E W Flensborg
Journal:  Acta Paediatr Scand       Date:  1983-09

5.  Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis.

Authors:  M E Hodson; C M Roberts; R J Butland; M J Smith; J C Batten
Journal:  Lancet       Date:  1987-01-31       Impact factor: 79.321

6.  Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis.

Authors:  N Hoiby; E W Flensborg; B Beck; B Friis; S V Jacobsen; L Jacobsen
Journal:  Scand J Respir Dis       Date:  1977-04

7.  Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.

Authors:  L J Chalkley; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

8.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

9.  Antibiotic treatment of Haemophilus influenzae and Haemophilus parainfluenzae infections in patients with cystic fibrosis.

Authors:  T Pressler; M Szaff; N Høiby
Journal:  Acta Paediatr Scand       Date:  1984-07

10.  Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.

Authors:  B E Scully; H C Neu; M F Parry; W Mandell
Journal:  Lancet       Date:  1986-04-12       Impact factor: 79.321

View more
  16 in total

Review 1.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 2.  Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  J A Balfour; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

Review 3.  Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors:  J H Paton; D S Reeves
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

4.  Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience.

Authors:  Elissa Charlotte Briggs; Thuan Nguyen; Michael Abraham Wall; Kelvin David MacDonald
Journal:  Clin Respir J       Date:  2011-08-09       Impact factor: 2.570

5.  Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin.

Authors:  U B Schaad; J Wedgwood-Krucko; K Guenin; U Buehlmann; R Kraemer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

Review 6.  Fluoroquinolones in the treatment of cystic fibrosis.

Authors:  N Høiby; S S Pedersen; T Jensen; N H Valerius; C Koch
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 7.  Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis.

Authors:  Matthew Hurley; Alan Smyth
Journal:  Ther Adv Respir Dis       Date:  2012-09-11       Impact factor: 4.031

Review 8.  Use of quinolones in pediatrics.

Authors:  U B Schaad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 9.  Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.

Authors:  M LeBel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 10.  The quinolones. An overview of their pharmacology.

Authors:  A Fitton
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.